McLean J. The thromboplastic action of cephalin. Am J Physiol 1916;41:250–257.
Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S–275S.
Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258–264.
Sabatine MS, Jang IK. Antithrombotic therapy in acute coronary syndromes. Acta Cardiol 1999;54:3–29.
Hirsh J. New anticoagulants. Am Heart J 2001;142:S3–S8.
Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503–516.
Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrinor clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381–386.
Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban' inhibition of thrombin. Blood 1998;92:2064–2074.
Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for the prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 2001;35:440–451.
Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000;20:756–770.
Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318–319.
Schwartz RP, Becker JP, Brooks RL, et al. The preclinical and clinical pharmacology of Novastan (argatroban): a small molecule, direct thrombin inhibitor. Clin Appl Thromb Hemost 1997;3:1–15.
Data on file. Argatroban Prescribing Information. Philadelphia: Smith-Kline Beecham, 2000.
Okamoto S, Hijikata A, Kikumoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805: the importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101:440–446.
Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990;67:1552–1561.
Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1989;81:219–225.
Jang IK, Gold HK, Leinbach RC, et al. Persistent inhibition of arterial thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coron Artery Dis 1992;3:407–414.
Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714–722.
Jang IK, Brown DF, Giugliano RP, et al. A multi-center, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: myocardial infarction with novastan and tPA (MINT) study. J Am Coll Cardiol 1999;33:1880–1885.
Vermeer F, Vahanian A, Fels PW, et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J Thromb and Thrombolysis 2000;10:233–240.
Behar S, Hod H, Kaplinsky E, for the ARGAMI-2 Study Group. Argatroban versus heparin as adjuvant therapy to thrombolysis for acute myocardial infarction: safety considerations-ARGAMI-2 study [abstract]. Circulation 1998;98(1, suppl):I453–I454.
Cody RJ-Results from late breaking clinical trials session at ACC'97. J Am Coll Cardiol 1997;30:1–7.
Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in pa-tients with unstable angina pectoris. J Am Coll Cardiol 1993;21:1039–1047.
Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141–145.
Januzzi JL, Jang IK. Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. J Thromb and Thrombolysis 1999;7:259–264.
Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838–1843.
Herrman JR, Suryapranata H, den Heijer P, Gabriel L, Kutryk MJ, Serruys PW. Argatroban during percutaneous transluminal coronary angioplasty: results of a dose-verification study. J Thromb and Thrombolysis 1996;3:367–375.
Lewis BE, Matthai W, Grassman ED, et al. Results of a Phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia [abstract]. Circulation 1997;96(8, suppl 1):I217.
Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb and Hemost 1997;23:531–534.
Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: a multicenter clinical trial of argatroban. J Thromb Thrombolysis 1995;2:131–136.
Ohteki H, Furukawa K, Ohnishi H, Narita Y, Sakai M, Doi K. Clinical experience of argatroban for anticoagulation in cardiovascular surgery. Jpn J Thorac Cardiovasc Surg 2000;48:39–46.
Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2000;14:445–457.
Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999;45:409–412.
Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435–440.
Cannon CP, Weintraub WS, Demopoulos LA, et al. TACTICS (treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy)- Thrombolysis In Myocardial Infarction 18 investigators: comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879–1887.